A Phase 1/2 Study Targeting Acquired Resistance Mechanisms in Patients with EGFR Mutant Non-Small Cell Lung CancerTrial Description: This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and anticancer activity of BLU-945, a selective EGFR inhibitor, as monotherapy or in combination with osimertinib
- Conditions: adenocarcinoma, antineoplastic agents, bronchial neoplasms, carcinoma, carcinoma bronchogenic, carcinoma non-small-cell lung, egfr activating mutation, egfr c797s, egfr exon 19 deletion, egfr gene mutation, egfr l858r, egfr mutation resulting in tyrosine kinase inhibitor resistance, egf-r positive non-small cell lung cancer, egfr t790m, lung diseases, lung neoplasms, neoplasms, neoplasms by histologic type, neoplasms by site, neoplasms nerve tissue, protein kinase inhibitors, respiratory tract disease, respiratory tract neoplasms, thoracic neoplasms
- Phase: I/II
- Trial ID: NCT04862780
- Protocol ID: 21-222